Investigating vision changes in early age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with early forms of age-related macular degeneration (AMD), which is a leading cause of visual impairment. It aims to identify functional markers of the disease by examining alterations in visual function through tests like microperimetry and multifocal electroretinogram. The study will include patients with specific retinal alterations while excluding those with more advanced disease or other complicating factors. By understanding these early changes, the research seeks to pave the way for future treatments to slow disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age
* Corrected visual acuity 10/10 in each eye
* Presence of retinal alteration(s) compatible with early (presence of macular drusen \< 125 μm) or intermediate (macular drusen \> 125 μm or pigmentary abnormalities) AMD in at least one of the two eyes :

  * Conventional "soft" or "hard" drusen
  * Cuticular drusen
  * Reticulated pseudo-drusen

Exclusion Criteria:

* Presence of geographic atrophy, even incipient, in one or both eyes
* Presence of patent or latent neovascularization visible on OCT b-scan or OCT-A in one or both eyes
* Compatibility of retinal signs with a "probable" differential diagnosis (bestrophinopathies, familial drusen, fundus flavimaculatus, fundus albipunctatus, hypovitaminosis A) in one or both eyes.
* Oculomotor pathology that may prevent proper performance of functional tests: nystagmus, oculomotor paralysis, in one or both eyes
* Neurological/neurodegenerative pathology that may prevent adequate performance of functional tests: advanced Parkinsonian syndromes, Benson's disease, Alzheimer's disease with visuomotor apraxia
* Other ophthalmological pathology that may affect anatomical and functional measurements: hypertonia / glaucoma or other optic neuropathy, media disorder causing reduced visual acuity, refraction \< -6.00D or \> +6.00D
* Other medical conditions preventing examinations or imaging (tremors, etc.)

Where it's running

• Hôpital Fondation A. de Rothschild
  Paris, France Recruiting

Study contacts

• Study coordinator: Amelie Yavchitz
• Email: ayavchitz@for.paris
• Phone: +33148036454

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

• C.001 for retinal degeneration: a first-in-human dose-escalation safety test

  A first-in-human study will test the safety and tolerability of a single subretinal injection of C.001 in adults with retinal diseases involving retinal pigment epithelium degeneration.

  Recruiting at 2 sites Phase 1 Cellio Therapeutics Inc · Beverly Hills, California and 2 other locations · NCT07594236

• Central microperimetry and radial OCT in geographic atrophy

  We will test whether central microperimetry and radial OCT scans can more accurately measure how geographic atrophy progresses toward the fovea in people with or at risk for GA from age-related macular degeneration.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07556406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.